Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P55 vs Cosentyx in Moderate to Severe Plaque Psoriasis
NCT06630559Phase 3Active, not recruiting
- Sponsor
- Celltrion
- Start
- May 2025
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CT-P55 in plaque psoriasis (2 arms), sponsored by Celltrion. Primary endpoint: Psoriasis Area and Severity Index at 8 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
CT-P55
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06630559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630559.